Table 2.

Statistical analysis assessing the impact of clinical- and treatment-related variables on outcome. SBRT: Stereotactic Body Radiotherapy. TAE/TACE: Transarterial Embolization/Transarterial Chemo-Embolization.

	Local Control	p	Progression-Free Survival	p	Distant Recurrence-Free Survival	p	Overall Survival	p
Gender
Male Female	11 months not reached	0.34	7 months 5 months	0.87	11 months 5 months	0.3	29 months 30 months	0.33
Age (median 75 years, range 52–85)
<75 ≥75	16 months 11 months	0.94	5 months 7 months	0.45	8 months 9 months	0.59	29 months 30 months	0.99
Child-Pugh Liver Disease Score
A B	11 months Not reached	0.94	7 months 2 months	0.18	11 months 9 months	0.98	30 months 16 months	0.027
Barcelona Staging System (BCLC)
A B	Not reached 11 months	0.17	7 months 5 months	0.21	8 months 9 months	0.99	30 months 29 months	0.44
HCV infection
Yes No	11 months 16 months	0.48	7 months 5 months	0.97	20 months 8 months	0.14	30 months 30 months	0.54
HBV infection
Yes No	11 months 16 months	0.72	5 months 5 months	0.58	9 months 7 months	0.60	29 months 29 months	0.54
Alcohol Abuse
Yes No	16 months 11 months	0.78	4 months 8 months	0.39	7 months 14 months	0.13	19 months 30 months	0.99
Number of treated lesions (median 1, range 1–3)
1 >1	12 months 16 months	0.88	7 months 6 months	0.44	10 months 9 months	0.37	31 months 22 months	0.2
Time from first diagnosis to randomization (median 60 months, range 4–280)
<60 ≥60	11 months 16 months	0.94	4 months 7 months	0.79	7 months 14 months	0.35	29 months 29 months	0.68
Treatment Arm
TAE/TACE SBRT	5 months not reached	0.002	4 months 8 months	0.035	14 months 8 months	0.49	29 months 30 months	0.28
Use of SBRT at any time after randomizatrion
Yes No	N/A	N/A	N/A	N/A	N/A	N/A	30 months 18 months	0.012
Any previous local treatment
Yes No	not reached 11 months	0.1	5 months 7 months	0.34	9 months 8 months	0.98	not reached 21 months	0.024

The numbers in bold indicate p-value < 0.05.